Novo Nordisk still expects to see a lot more growth in the second half.Novo Nordisk (NVO 0.64%) recently posted its latest earnings numbers, and they fell short of Wall Street's expectations. Investors had high hopes for the company, which is known for its popular diabetes treatment, Ozempic, and its weight loss drug, Wegovy. But they may be having second thoughts about its growth prospects and its ability to be a continually top-performing investment in light of its recent performance.Could this recent ear ...